BCAR1 (Ab-410) Antibody

What is BCAR1 and why is the Ab-410 antibody important in cancer research?

BCAR1 (Breast Cancer Anti-Estrogen Resistance 1), also known as p130Cas, is a scaffold protein that plays a central coordinating role in tyrosine kinase-based signaling related to cell adhesion. It is implicated in cell migration, invasion, and survival, with significant involvement in promoting tumor growth and metastasis .

The Ab-410 antibody is specifically designed to target the region around the tyrosine 410 phosphorylation site of BCAR1, which is a critical regulatory site for BCAR1 activation. This makes it an essential tool for studying the mechanisms of breast cancer progression and anti-estrogen resistance .

What are the basic applications for BCAR1 (Ab-410) Antibody?

The BCAR1 (Ab-410) Antibody has been validated for multiple applications:

The antibody has been tested and confirmed to react with human, mouse, and rat samples .

How does the BCAR1 (Ab-410) Antibody differ from phospho-specific BCAR1 antibodies?

The BCAR1 (Ab-410) Antibody is generated using a non-phosphopeptide derived from the region around tyrosine 410 of human p130 Cas (sequence: G-V-T-A-V) . It detects the total BCAR1 protein, regardless of phosphorylation status.

In contrast, phospho-specific antibodies like Phospho-BCAR1-Y410 are designed to exclusively recognize BCAR1 when phosphorylated at tyrosine 410 . The phospho-specific antibodies are critical for studying the activation state of BCAR1, while the Ab-410 antibody provides information about total protein expression levels .

How can I validate the specificity of BCAR1 (Ab-410) Antibody in my experimental system?

Validating antibody specificity is crucial for reliable results. For BCAR1 (Ab-410) Antibody, consider these approaches:

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide before application. If the antibody is specific, the signal should be significantly reduced or eliminated. This has been demonstrated in Western blot analysis of HuvEc cells .

• Knockdown/knockout validation: Use siRNA, shRNA, or CRISPR/Cas9 to reduce or eliminate BCAR1 expression in your cells, then perform Western blotting to confirm signal reduction.

• Multiple antibody approach: Compare results with other BCAR1 antibodies targeting different epitopes to confirm detection patterns.

• Positive controls: Include samples known to express high levels of BCAR1, such as HeLa cells .

• Molecular weight verification: Confirm that the detected band appears at the expected molecular weight (~93 kDa calculated, often observed at ~130-140 kDa due to post-translational modifications) .

What is the relationship between BCAR1 phosphorylation at Y410 and resistance to anti-estrogen therapies in breast cancer?

BCAR1 phosphorylation, particularly at tyrosine residues including Y410, is intimately connected with anti-estrogen resistance mechanisms in breast cancer. Research has shown that:

• BCAR1 and BCAR3 work together to promote antiestrogen resistance and malignancy in breast cancer cells .

• The tight association between BCAR1 and BCAR3 is necessary for downstream signaling events required for antiestrogen resistance, including ERK1/2 activation .

• Mutations that disrupt the BCAR1-BCAR3 association impair the signaling needed for antiestrogen resistance .

• Phosphorylation at Y410 facilitates the recruitment of adaptor proteins such as Crk and Nck to the phosphorylated substrate domain, activating downstream signaling cascades that promote cell survival and proliferation despite the presence of anti-estrogen compounds .

These findings suggest that the BCAR1-BCAR3 complex and associated signaling events represent promising therapeutic targets in breast cancer .

How can BCAR1 (Ab-410) Antibody be used to investigate the crosstalk between BCAR1 and other signaling pathways?

The BCAR1 (Ab-410) Antibody can be instrumental in examining the interplay between BCAR1 and other signaling networks:

• Co-immunoprecipitation studies: Use the antibody to pull down BCAR1 complexes and identify associated proteins using mass spectrometry or Western blotting for suspected interaction partners like BCAR3, SRC, and FAK .

• Dual immunofluorescence: Combine BCAR1 (Ab-410) Antibody with antibodies against other signaling molecules to visualize co-localization in cells or tissues.

• Signaling pathway analysis: Monitor changes in BCAR1 expression/localization following manipulation of other pathways (e.g., growth factor signaling, integrin signaling) using inhibitors, stimulators, or genetic approaches.

• Phosphorylation profiling: Use the Ab-410 antibody alongside phospho-specific antibodies (pY410, pY165) to track multiple phosphorylation events in response to various stimuli .

• Sequential immunoprecipitation: Perform tandem immunoprecipitations to isolate specific subcomplexes containing BCAR1 and other proteins of interest.

Recent studies have highlighted BCAR1's involvement in the BCAR3-mediated inhibition of TGFβ signaling, suggesting an important role in regulating cellular responses to growth inhibitory signals .

What are the optimal conditions for using BCAR1 (Ab-410) Antibody in Western blotting?

For optimal Western blot results with BCAR1 (Ab-410) Antibody:

• Sample preparation:

  • Use RIPA or NP-40 based lysis buffers containing phosphatase inhibitors

  • Include protease inhibitors to prevent protein degradation

  • Centrifuge lysates at high speed (>10,000 g) to remove insoluble material

• Gel electrophoresis:

  • Use 7.5% SDS-PAGE gels for better resolution of high molecular weight proteins

  • Load 10-30 μg of total protein per lane

• Transfer and blocking:

  • Transfer to PVDF membranes for optimal protein binding

  • Block with 5% BSA in TBST (preferred over milk for phosphoprotein detection)

• Antibody incubation:

  • Dilute BCAR1 (Ab-410) Antibody 1:500-1:3000 in blocking buffer

  • Incubate overnight at 4°C for best results

  • Wash extensively with TBST (3-5 washes, 5-10 minutes each)

  • Use HRP-conjugated anti-rabbit secondary antibody at 1:2000-1:5000 dilution

• Detection:

  • Enhanced chemiluminescence is suitable for most applications

  • Expected molecular weight is 93 kDa (calculated), but BCAR1 typically migrates at approximately 130-140 kDa due to post-translational modifications

What controls should be included when using BCAR1 (Ab-410) Antibody in immunohistochemistry?

When performing immunohistochemistry with BCAR1 (Ab-410) Antibody, include these essential controls:

• Positive tissue control: Breast carcinoma tissue has been validated for BCAR1 expression and is recommended as a positive control .

• Negative control omitting primary antibody: Apply only secondary antibody to confirm specificity of detection system.

• Peptide competition control: Pre-incubate the antibody with immunizing peptide to validate specificity.

• Isotype control: Use matched concentration of non-specific rabbit IgG to identify any non-specific binding.

• Tissue processing controls: Include tissues processed identically to experimental samples.

Optimal dilution for immunohistochemistry is 1:50-1:100 . Antigen retrieval methods (such as citrate buffer pH 6.0 or EDTA buffer pH 9.0) may be necessary for formalin-fixed, paraffin-embedded tissues.

How can I optimize detection of phosphorylated versus total BCAR1 in cell signaling studies?

To effectively distinguish between phosphorylated and total BCAR1 in signaling studies:

• Stimulation conditions:

  • Use pervanadate treatment of cells (e.g., HeLa cells) to enhance tyrosine phosphorylation for positive controls

  • For physiological activation, stimulate cells with growth factors (EGF, PDGF), integrin engagement, or mechanical stress

• Sample preparation:

  • Rapid lysis is critical to preserve phosphorylation status

  • Include phosphatase inhibitors (sodium orthovanadate, sodium fluoride, β-glycerophosphate)

  • Maintain samples at 4°C throughout processing

• Antibody selection and application:

  • Use BCAR1 (Ab-410) Antibody to detect total BCAR1 protein

  • Use phospho-specific antibodies (such as Phospho-BCAR1-Y410) to detect activated forms

  • Consider dual detection methods (e.g., fluorescent secondary antibodies with different colors)

• Quantification approach:

  • Calculate the ratio of phosphorylated to total BCAR1 rather than absolute phosphorylation levels

  • Use image analysis software for densitometry measurements

  • Normalize to appropriate loading controls

• Time course analysis:

  • Include multiple time points (0, 5, 15, 30, 60 minutes) after stimulation to capture phosphorylation dynamics

  • Consider both rapid and sustained phosphorylation events

This approach enables researchers to distinguish between changes in BCAR1 expression versus activation, providing more meaningful insights into signaling mechanisms .

What experimental approaches can be used to study the functional significance of BCAR1 Y410 phosphorylation?

To investigate the functional importance of BCAR1 Y410 phosphorylation:

• Site-directed mutagenesis:

  • Generate Y410F mutants (cannot be phosphorylated) for functional studies

  • Create phosphomimetic mutants (Y410E or Y410D) to simulate constitutive phosphorylation

  • Express these constructs in appropriate cell models using lentiviral systems

• Pharmacological approaches:

  • Use SRC family kinase inhibitors to reduce BCAR1 phosphorylation

  • Compare effects with FAK inhibitors to distinguish between different phosphorylation mechanisms

• Cellular assays:

  • Migration assays (wound healing, Boyden chamber) to assess motility effects

  • Antiestrogen resistance assays in breast cancer cell lines (e.g., MCF7)

  • Cell spreading and adhesion assays to examine cytoskeletal reorganization

  • Proliferation and survival assays under stress conditions

• Signaling pathway analysis:

  • Monitor ERK1/2 activation, which has been linked to the BCAR1-BCAR3 complex

  • Assess AKT phosphorylation and downstream survival pathways

  • Examine focal adhesion dynamics and turnover

• In vivo approaches:

  • Xenograft models with cells expressing wild-type versus mutant BCAR1

  • Analysis of tumor growth, invasion, and metastasis

  • Assessment of response to antiestrogen therapies

These multi-faceted approaches can provide comprehensive insights into how Y410 phosphorylation contributes to BCAR1's functions in normal and pathological contexts .

What are common issues when using BCAR1 (Ab-410) Antibody and how can they be resolved?

How can I ensure reproducible results when studying BCAR1 phosphorylation dynamics?

To achieve consistent and reliable results in BCAR1 phosphorylation studies:

• Standardize cell culture conditions:

  • Maintain consistent cell density (70-80% confluence ideal)

  • Use cells at similar passage numbers

  • Synchronize cells when possible (serum starvation for 16-24 hours)

  • Document exact media composition and additives

• Control stimulation parameters:

  • Prepare fresh stocks of activators/inhibitors

  • Standardize concentrations and exposure times

  • Include appropriate vehicle controls

  • Maintain consistent temperature during treatments

• Optimize lysis conditions:

  • Use ice-cold buffers with freshly added inhibitors

  • Standardize cell scraping/collection methods

  • Process all samples identically and simultaneously

  • Avoid repeated freeze-thaw cycles of lysates

• Technical considerations:

  • Run replicate experiments on different days

  • Include internal controls in each experiment

  • Use the same lot of antibodies when possible

  • Document all experimental parameters meticulously

• Quantitative analysis:

  • Use digital image capture with linear dynamic range

  • Employ consistent analysis parameters

  • Normalize to appropriate housekeeping proteins

  • Apply statistical tests appropriate for your data type

What are the most effective systems for studying BCAR1 function in cancer progression models?

Several experimental systems have proven valuable for investigating BCAR1's role in cancer:

• Cell line models:

  • MCF7 breast cancer cells: Established model for antiestrogen resistance studies

  • HeLa cells: Express high levels of BCAR1 and respond well to phosphorylation stimuli

  • NIH/3T3 cells: Useful for studying BCAR1 in fibroblast migration and invasion

  • HuvEc cells: Appropriate for examining BCAR1 in endothelial cell functions

• 3D culture systems:

  • Matrigel invasion assays for assessing metastatic potential

  • Organoid cultures to better recapitulate tumor microenvironment

  • Spheroid models for studying cell-cell interactions

• Genetic manipulation approaches:

  • Lentiviral expression systems for stable integration of wild-type or mutant BCAR1

  • CRISPR/Cas9 for knockout or knock-in studies

  • Inducible expression systems for temporal control of expression

• In vivo models:

  • Xenograft models in immunocompromised mice

  • Patient-derived xenografts for greater clinical relevance

  • Genetically engineered mouse models with tissue-specific alterations

• Clinical samples:

  • Human breast carcinoma tissue for immunohistochemical validation

  • Correlation of BCAR1 expression/phosphorylation with treatment response

  • Analysis of primary versus metastatic lesions

Each system offers unique advantages for specific research questions, but integrating data from multiple models provides the most comprehensive understanding of BCAR1's functions in cancer progression .

How might BCAR1 (Ab-410) Antibody contribute to personalized medicine approaches for breast cancer?

The BCAR1 (Ab-410) Antibody could advance personalized medicine in several ways:

• Biomarker development:

  • Using IHC with this antibody to assess BCAR1 expression levels in patient tumors

  • Correlating expression patterns with response to antiestrogen therapies

  • Developing predictive algorithms combining BCAR1 with other biomarkers

• Therapeutic resistance mechanisms:

  • Investigating how BCAR1 contributes to treatment resistance

  • Identifying patient subgroups likely to develop resistance

  • Monitoring changes in BCAR1 expression/localization during treatment

• Combination therapy approaches:

  • Exploring how targeting BCAR1-associated pathways might enhance conventional therapies

  • Determining which patients would benefit from specific combination approaches

  • Developing companion diagnostics for emerging targeted therapies

• Metastasis prediction:

  • Assessing whether BCAR1 expression/phosphorylation patterns correlate with metastatic potential

  • Creating risk stratification tools based on BCAR1 and associated molecules

  • Identifying patients who might benefit from more aggressive initial treatment

• Drug development:

  • Supporting research into compounds targeting the BCAR1-BCAR3 complex

  • Enabling screening assays for molecules that inhibit BCAR1 phosphorylation at Y410

  • Facilitating evaluation of drug efficacy in preclinical models

These applications highlight the potential for BCAR1 (Ab-410) Antibody to bridge fundamental research with clinical applications in breast cancer management .

What emerging technologies might enhance the utility of BCAR1 (Ab-410) Antibody in research?

Several cutting-edge technologies could expand the applications of BCAR1 (Ab-410) Antibody:

• Single-cell analysis:

  • Single-cell Western blotting to examine cell-to-cell variation in BCAR1 expression

  • Mass cytometry (CyTOF) with metal-conjugated antibodies for multi-parameter analysis

  • Integration with single-cell transcriptomics for correlated protein-RNA studies

• Advanced imaging techniques:

  • Super-resolution microscopy to visualize BCAR1 within focal adhesion complexes

  • Live-cell imaging with conjugated nanobodies derived from the Ab-410 sequence

  • Correlative light and electron microscopy for ultrastructural localization

• Proteomics approaches:

  • Proximity labeling methods (BioID, APEX) using BCAR1 as bait to identify interaction partners

  • Phosphoproteomics to map the complete BCAR1 signaling network

  • Targeted proteomics with parallel reaction monitoring for absolute quantification

• Spatial biology:

  • Multiplexed immunohistochemistry to examine BCAR1 in the context of tumor microenvironment

  • Digital spatial profiling to map BCAR1 distribution across tissue regions

  • 3D tissue imaging with clearing techniques for volumetric analysis

• Functional genomics integration:

  • CRISPR screens combined with BCAR1 profiling to identify genetic dependencies

  • Integrative multi-omics approaches linking BCAR1 to genomic alterations

  • Systems biology modeling of BCAR1 signaling networks